Early Lymphocyte Recovery Predicts Superior Survival after Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma: A Prospective Study  Luis F. Porrata, David J. Inwards, Stephen M. Ansell, Ivana N. Micallef, Patrick B. Johnston, Dennis A. Gastineau, Mark R. Litzow, Jeffrey L. Winters, Svetomir N. Markovic  Biology of Blood and Marrow Transplantation  Volume 14, Issue 7, Pages 807-816 (July 2008) DOI: 10.1016/j.bbmt.2008.04.013 Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 (a) OS of patients with an ALC-15 ≥500 cells/μL versus patients with an ALC-15 <500 cells/μL. The median OS was not reached in the group of patients with an ALC-15 ≥500 cells/μL and in 5.4 months with the group of patients with an ALC-15 <500 cells/μL. The OS rates at 3 years were 80% and 37%, respectively (P < .0001). (b) PFS of patients with an ALC-15 ≥500 cells/μL versus patients with an ALC-15 <500 cells/μL. The median PFS was not reached in the group of patients with an ALC-15 ≥500 cells/μL and in 3.3 months with the group of patients with an ALC-15 <500 cells/μL. The PFS rates at 3 years were 63% and 13%, respectively (P < .0001). Biology of Blood and Marrow Transplantation 2008 14, 807-816DOI: (10.1016/j.bbmt.2008.04.013) Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Actuarial risk of relapse for ALC-15 lymphocyte subsets. Biology of Blood and Marrow Transplantation 2008 14, 807-816DOI: (10.1016/j.bbmt.2008.04.013) Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 (a) OS of patients with an NK-15 ≥80 cells/μL versus patients with an NK-15 <80 cells/μL. The median OS was not reached in the group of patients with an NK-15 ≥80 cells/μL and 5 months with the group of patients with an NK-15 <500 cells/μL. The OS rates at 3 years were 76% and 36%, respectively (P < .0001). (b) PFS of patients with an NK-15 ≥80 cells/μL versus patients with an NK-15 <80 cells/μL. The median PFS was not reached in the group of patients with an NK-15 ≥80 cells/μL and 3 months with the group of patients with an NK-15 <500 cells/μL. The OS rates at 3 years were 57% and 9%, respectively (P < .0001). Biology of Blood and Marrow Transplantation 2008 14, 807-816DOI: (10.1016/j.bbmt.2008.04.013) Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions